TW200302732A - Treatment of male sexual dysfunction - Google Patents

Treatment of male sexual dysfunction Download PDF

Info

Publication number
TW200302732A
TW200302732A TW092101731A TW92101731A TW200302732A TW 200302732 A TW200302732 A TW 200302732A TW 092101731 A TW092101731 A TW 092101731A TW 92101731 A TW92101731 A TW 92101731A TW 200302732 A TW200302732 A TW 200302732A
Authority
TW
Taiwan
Prior art keywords
ejaculation
oxytocin
receptor
selective
agent
Prior art date
Application number
TW092101731A
Other languages
English (en)
Chinese (zh)
Inventor
Alasdair Mark Naylor
Rachel Jane Russell
Stephen Derek Albert Street
Kim-Wah Tang
Der Graaf Pieter Hadewijn Van
Christopher Peter Wayman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of TW200302732A publication Critical patent/TW200302732A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW092101731A 2002-01-31 2003-01-27 Treatment of male sexual dysfunction TW200302732A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202282.0A GB0202282D0 (en) 2002-01-31 2002-01-31 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
TW200302732A true TW200302732A (en) 2003-08-16

Family

ID=9930155

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092101731A TW200302732A (en) 2002-01-31 2003-01-27 Treatment of male sexual dysfunction

Country Status (16)

Country Link
EP (1) EP1470115A1 (xx)
JP (3) JP2005525321A (xx)
KR (2) KR100829262B1 (xx)
CN (1) CN100500658C (xx)
AU (1) AU2003201471B2 (xx)
BR (1) BR0307337A (xx)
CA (1) CA2474590A1 (xx)
GB (1) GB0202282D0 (xx)
HK (1) HK1073109A1 (xx)
IL (2) IL162822A0 (xx)
MX (1) MXPA04007434A (xx)
NZ (1) NZ546408A (xx)
PL (1) PL371415A1 (xx)
TW (1) TW200302732A (xx)
WO (1) WO2003064402A1 (xx)
ZA (1) ZA200405208B (xx)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3646871A1 (en) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Treatment and prevention of premature ejaculation (pe)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
EP0679084A1 (en) * 1992-12-23 1995-11-02 Merck & Co. Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
EP0614894A1 (en) * 1993-03-12 1994-09-14 Merck & Co. Inc. Process for the synthesis of substituted amide derivatives of piperazinylcamphorsulfonyl oxytocin antagonists
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
US20020028799A1 (en) * 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction

Also Published As

Publication number Publication date
CA2474590A1 (en) 2003-08-07
JP2010209075A (ja) 2010-09-24
NZ546408A (en) 2007-10-26
KR20040079958A (ko) 2004-09-16
IL162822A (en) 2010-11-30
JP2013151511A (ja) 2013-08-08
MXPA04007434A (es) 2004-10-11
IL162822A0 (en) 2005-11-20
JP2005525321A (ja) 2005-08-25
KR20080011232A (ko) 2008-01-31
ZA200405208B (en) 2005-08-31
KR100829262B1 (ko) 2008-05-13
WO2003064402A1 (en) 2003-08-07
CN1625553A (zh) 2005-06-08
AU2003201471B2 (en) 2009-03-26
CN100500658C (zh) 2009-06-17
BR0307337A (pt) 2004-12-07
HK1073109A1 (en) 2005-09-23
PL371415A1 (en) 2005-06-13
GB0202282D0 (en) 2002-03-20
EP1470115A1 (en) 2004-10-27

Similar Documents

Publication Publication Date Title
JP2004502735A (ja) 男性の性機能障害の治療
KR20080034877A (ko) 비만 치료를 위한 약리학적 샤폐론
JP2013138679A (ja) β１−アドレナリン作動性レセプター抗体を阻害する変異体二重環化レセプターペプチド
US20170275249A1 (en) Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
US20150072995A1 (en) Treatment of male sexual dysfunction
JP4214057B2 (ja) 性機能障害を治療するための選択的ドーパミンｄ３受容体アゴニスト
JP2004522720A (ja) 雄性性的機能障害の処置
TW200302732A (en) Treatment of male sexual dysfunction
JP3602799B2 (ja) アッセイ法
JP2004517046A (ja) 医薬
AU2003201471A1 (en) Treatment of male sexual dysfunction
JP2005021151A (ja) スクリーニング方法
JP2005518346A (ja) ドパミン作動性ニューロンの調節
US20040185094A1 (en) Pharmaceutical
EP1445315A1 (en) Human and mammalian stem cell-derived neuronal survival polypeptides
WO2006118289A1 (ja) 抗うつ作用を有する化合物の同定方法
ZA200304460B (en) Treatment of male sexual dysfunction.